Paclitaxel (Taxol) Resistance in Breast Cancer Cells.
Abstract
With reference to the three tasks of this project, as noted in the prior report, we have completed task 1 (Development of resistance to taxol alone). This current report focuses on task 2 (double selection of resistance to taxol and PSC 833) and task 3 (investigation of taxol resistant mutants). We have developed cellular models of breast cancer cells resistant to both taxol and the combination of taxol with PSC 833, a potent inhibitor of MDR1. These cells demonstrate alterations in apoptosis regulating proteins as well as tubulin isotypes. The relationship of these changes to the resistance phenotype of these cells is currently being explored.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1997
- Accession Number
- ADA349565
Entities
People
- Branimir I. Sikic
Organizations
- Stanford University